Clinical Study

Accuracy of Patient Opioid Use Reporting at the Time of Medical Cannabis License Renewal

Jacob M. Vigil,1 Sarah S. Stith,2 and Anthony P. Reeve3

1Department of Psychology, University of New Mexico, Albuquerque, NM, USA
2Department of Economics, University of New Mexico, Albuquerque, NM, USA
3Industrial Rehabilitation Clinics, Albuquerque, NM, USA

Correspondence should be addressed to Jacob M. Vigil; vigilj@unm.edu

Received 27 October 2017; Accepted 11 January 2018; Published 28 January 2018

1.Introduction

The current opioid epidemic has resulted in the immediate need for alternative pain treatments [1, 2], such as medical cannabis [3–5], which has been authorized in one form or another in most of the states of the U.S. However, the decision to authorize a patient for enrollment in a state-sanctioned medical cannabis program can be challenging due to the dearth of extant clinical research on the likely health outcomes of enrollment for patients overall, as well as for potentially higher risk subgroups such as older patients. Another uncertainty is the accuracy of symptom reporting by patients often on prescription opioids and seeking to obtain legal access to an additional addictive, controlled substance that is widely used for nonmedical purposes in the general population and hence has the potential for nonmedical abuse and diversion.

In our (APR) rehabilitation clinic, where we authorize patients for initial and continued enrollment in the New Mexico Medical Cannabis Program (NMMCP), we noticed a pattern recently described in the literature [6, 7], whereby a number of patients claimed to have replaced their prescription opioids in favor of using cannabis for treating chronic pain. In order to assess whether those anecdotal reports were, in fact, true and occurring over a broader spectrum of patients rather than simply in a few incidental cases, we conducted a pragmatic convenience study among people authorized to use cannabis for treating a chronic pain condition comparing patient reporting to their Prescription Monitoring Program (PMP) opioid prescription records.

2.Methods

One year following enrollment in the NMMCP, 131 patients (mean age = 54; 54% male, 65% chronic back pain, 27% other
n = 64 opioid prescription (OP) users

n = 35 reported OP quitters

n = 26 actual OP quitters

Figure 1: Diagram of patient-reported and PMP-recorded opioid prescriptions. The percentages refer to the proportion of that subsample (N) responding as specified. "Patient-reported" refers to patients’ queried responses at the time of NMMCP enrollment renewal; "PMP" refers to categorizations based on evidence in the PMP records. Patients were asked about preenrollment use. PMP records covering the six month period prior to enrollment were used to measure preenrollment PMP activity; PMP records for months 12 and 13 were used to evaluate elimination. Red-colored patient rates indicate misreporting; red outlines indicate repeated misreporting.

chronic musculoskeletal pain, 4% fibromyalgia; 2% arthritis, and 2% chronic headaches) from a single rehabilitation clinic in Albuquerque, NM, completed a brief survey asking (1) whether or not they were using prescription opioids prior to enrollment in the NMMCP (“When you began the program, did you use narcotics for pain management?”) and (2) if they were able to cease the use of all prescription opioids by the time of renewal (after 12 months enrolled in the NMMCP). While enrolled in the NMMCP, patients received no direct medical supervision over their cannabis usage (e.g., frequency, dosage, or type of cannabis product), nor were they provided any explicit instructions for modifying (e.g., reducing) their opioid usage. Pre-enrollment prescription opioid use was verified with PMP evidence of any opioid prescriptions in the 6 months leading up to enrollment in order to capture recent prescription activity, and current opioid use was verified with evidence of any opioid prescription in month 12 or 13 after enrollment.

3. Results

Figure 1 shows that over three-fourths (76%) of the patients we observed reported using prescription opioids prior to enrollment in the NMMCP; however, the PMP records showed that only half (49%) of the patients were actually prescribed opioids in the six months prior to enrollment. Of the 64 patients with verifiable opioid prescriptions prior to MCP enrollment, 35 (55%) patients reported having eliminated the use of prescription opioids (in favor of using cannabis for treating their chronic pain conditions) by the time of MCP enrollment renewal. PMP records show that 22 (63%) of these patients did, indeed, show no PMP evidence of opioid prescriptions in months 12-13 after enrollment, and an additional 4 patients that misreported not eliminating prescription opioid usage actually showed no verifiable records of opioid prescriptions. This resulted in a final count of 26 patients (41% of all patients with verifiable preenrollment opioid use) showing no PMP records of opioid prescriptions at the time of their first annual MCP renewal visit. Follow-up independent samples t-tests revealed, unlike other studies showing a greater preponderance of misreporting medication use among males [8], no gender or age differences (contrasting patients above and below 55yrs) in the accuracy of patient-reported opioid prescription use among patients claiming to have eliminated the use of prescription opioids (p’s = 0.629 and 0.901, resp.).

4. Discussion

Misuse, underreporting, and noncompliance of medication use among chronic pain patients are notoriously common [9–14]; however, at least in the context of seeking a renewal of their medical cannabis license, the rates of misreporting the ability to substitute the use of opioids in favor of medical cannabis appeared to be relatively low. In addition to documenting the consistent accuracy of patient opioid use reporting in the context of medical cannabis license renewal, the patterns in the PMP data support exploring the possibility of using medical cannabis to treat chronic pain as a substitute for opioids. Colocalization and potential
synergistic effects of μ-opioid and CB1 receptors in various regions of the central nervous system make the adjunct use of raw natural cannabis and cannabis formulations viable options for future research on their analgesic therapeutic potential [3–5, 15]. Recent studies have shown that state-enacted laws enabling patients to legally obtain and use medical cannabis are associated with significant (up to 33%) reductions in opioid-related deaths in those regions [16, 17]. Contributing to a growing literature that shows an association between significant reductions in opioid prescriptions and medical cannabis [6, 18], we found that the majority of patients reporting to be using medical cannabis instead of prescription opioids for treating their chronic pain have PMP records consistent with this claim. Our pragmatic observation study using a convenience sample is superior to nonrepresentative samples used in RCTs, because they do not capture actual use of opioids and cannabis among “real” patients. Of course, the obvious limitations of our approach are that opioid prescribing does not automatically equate to patient opioid use (e.g., diversion) and conversely a previous prescription could be used by patients at a later date to obtain opioids. No study to date has compared the long-term effects of using prescription opioids versus medical cannabis for treating chronic pain. However, from a harm reduction standpoint considering the emergent opiate crisis in this U.S. along with the notable risks of abuse [14] and overdose [19, 20], alternative treatments for chronic pain need to be explored and researched, and medical cannabis may be a viable alternative. Unfortunately, federal barriers continue to exist which largely restrict the ability to conduct practical medical cannabis research [21].

Abbreviations
PMP: Prescription Monitoring Program
NMMCP: New Mexico Medical Cannabis Program.

Ethical Approval
The data had already been collected and de-identified as part of normal patient monitoring protocols prior to inception of the study, which was approved by the University of New Mexico Institutional Review Board.

Disclosure
All the authors have full access to all the de-identified data in the study and take responsibility for the integrity of the data and the accuracy of the data analyses.

Conflicts of Interest
The authors declare that they have no conflicts of interest.

References
[1] CDC, Wide-Ranging Online Data for Epidemiologic Research (WONDER), CDC, National Center for Health Statistics, Atlanta, GA, USA, 2016, http://wonder.cdc.gov.
[2] R. A. Rudd, P. Seth, F. David, and L. Scholl, “Increases in drug and opioid-involved overdose deaths—United States, 2010–2015,” Morbidity and Mortality Weekly Report, vol. 65, pp. 1445–1452, 2016.
[3] Y. L. Hurd, “Cannabidiol: swinging the marijuana pendulum from ‘weed’ to medication to treat the opioid epidemic,” Trends in Neurosciences, vol. 40, no. 3, pp. 124–127.
[4] G. G. Macedonio, A. Stefanucci, C. Macchialini, S. Mirzaie, E. Novellino, and A. Mollica, “Hemopressin peptides as modulators of the endocannabinoid system and their potential applications as therapeutic tools,” Protein and Peptide Letters, vol. 23, no. 12, pp. 1045–1051, 2016.
[5] A. Mollica, S. Pelliccia, V. Famiglieni et al., “Exploring the first Rimonabant analog-opioid peptide hybrid compound, as bivalent ligand for CB1 and opioid receptors,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 32, no. 1, pp. 444–451, 2017.
[6] S. Haroutounian, Y. Ratz, Y. Ginosar et al., “The effect of medicinal cannabis on pain and quality-of-life outcomes in chronic pain: a prospective open-label study,” Clinical Journal of Pain, vol. 32, no. 12, pp. 1036–1043, 2016.
[7] B. J. Piper, R. M. DeKeuster, M. L. Beals et al., “Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep,” Journal of Psychopharmacology, vol. 31, no. 5, pp. 569–575, 2017.
[8] S. E. McCabe, B. T. West, C. J. Teter, and C. J. Boyd, “Trends in medical use, diversion, and nonmedical use of prescription medications among college students from 2003 to 2013; connecting the dots,” Addictive Behaviors, vol. 39, no. 7, pp. 1176–1182, 2014.
[9] T. Ives, P. Chelminski, C. Hammett-Stabler et al., “Predictors of opioid misuse in patients with chronic pain: a prospective cohort study,” BMC Health Services Research, vol. 6, p. 46, 2006.
[10] K. Kipping, C. Maier, H. H. Bussemas, and A. Schwarzer, “Medication compliance in patients with chronic pain,” Pain Physician, vol. 17, no. 1, pp. 81–94, 2014.
[11] L. Manchkanti, R. Manchukonda, K. S. Damron, D. Brandon, C. D. McManus, and K. Cash, “Does adherence monitoring reduce controlled substance abuse in chronic pain patients?,” Pain Physician, vol. 9, no. 1, pp. 57–60, 2006.
[12] S. E. Melanson, M. L. Kredlow, and P. Jarolim, “Analysis and interpretation of drug testing results from patients on chronic pain therapy: a clinical laboratory perspective,” Clinical Chemistry and Laboratory Medicine, vol. 47, no. 8, pp. 971–976, 2009.
[13] E. Michna, R. N. Jamison, L. D. Pham et al., “Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings,” Clinical Journal of Pain, vol. 23, no. 2, pp. 173–179, 2007.
[14] K. E. Vowles, M. L. McIntee, P. S. Julnes, T. Frohe, J. P. Ney, and D. N. van der Goes, “Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis,” Pain, vol. 156, no. 4, pp. 569–576, 2015.
[15] J. L. Scavone, R. C. Sterling, and E. J. Van Bockstaele, “Cannabinoid and opioid interactions: implications for opiate dependence and withdrawal,” Neuroscience, vol. 248, pp. 637–654, 2013.
[16] M. A. Bachhuber, B. Saloner, C. O. Cunningham et al., “Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010,” JAMA Internal Medicine, vol. 174, no. 10, pp. 1668–1673, 2014.
fatally injured drivers,” *American Journal of Public Health*, vol. 106, no. 11, pp. 2032–2037, 2016.

[18] A. C. Bradford and W. D. Bradford, “Medical cannabis laws reduce prescription medication use in medicare part D,” *Health Affairs*, vol. 35, no. 7, pp. 1230–1236, 2016.

[19] W. D. Chey, L. Webster, M. Sostek, J. Lappalainen, P. N. Barker, and J. Tack, “Naloxegol for opioid-induced constipation in patients with non-cancer pain,” *New England Journal of Medicine*, vol. 370, no. 25, pp. 2387–2396, 2014.

[20] R. Chou, J. A. Turner, E. B. Devine et al., “The effectiveness and risks of long-term opioid therapy for chronic pain: a systematic review for a National Institutes of Health Pathways to Prevention Workshop,” *Annals of Internal Medicine*, vol. 162, no. 4, pp. 276–286, 2015.

[21] S. S. Stith and J. M. V. Vigil, “Federal barriers to Cannabis research,” *Science*, vol. 352, no. 6290, p. 1182, 2016.